சாரா கேடி News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from சாரா கேடி. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In சாரா கேடி Today - Breaking & Trending Today
Science’s COVID-19 reporting is supported by the Heising-Simons Foundation. When the Kremlin last month said Russian President Vladimir Putin had received the first dose of a homegrown COVID-19 vaccine, a guessing game began. Had he gotten Sputnik V, which Russia had given emergency use authorization a world first in August 2020 after testing in just 79 patients? Or had Putin been given another COVID-19 vaccine that Russia had sanctioned with much less fanfare and with equally sparse evidence that it works? Putin and state officials wouldn’t say, but Russia’s second COVID-19 vaccine, known as EpiVacCorona and first authorized in October 2020, has begun to emerge from the shadow of Sputnik V, bringing controversy of its own. Developed by VECTOR, the famed State Research Center of Virology and Biotechnology that once studied bioweapons and now is one of two global repositories of the eradicated smallpox virus, the vaccine is key to the country’s plans to combat the p ....
Good news: EU nations have resumed Oxford vaccine. Bad news: They don't have enough doses scroll.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from scroll.in Daily Mail and Mail on Sunday newspapers.
About a dozen COVID-19 vaccines have been approved around the world, providing a possible path out of the pandemic. But hurdles have emerged, including logistical issues around vaccine rollouts, a rising tide of worrisome variants, and uncertainty around the longevity of immunity. New trials underway to test combinations of different manufacturers’ vaccines seek to overcome some of these challenges. “It’s really exciting that we have these combination trials,” says Sarah Caddy, a viral immunologist at the University of Cambridge. “If we can use different vaccines, that opens opportunities for vaccinating more people.” In addition, she notes, “there’s some evidence that mixing and matching vaccines could give us better immune responses.” ....
From virus transmission to infection, DW answers some of the most common questions about COVID-19 vaccines. As new virus variants emerge, the efficacy of current vaccines could change. ....
The optimistic mood around COVID-19 vaccine rollouts has been clouded by new variants of the virus, which could trample the efficacy of vaccines or escape them entirely. Already, recent trial results from Johnson & Johnson and from Novavax suggest that a variant that first arose in South Africa (B.1.351) and probably a variant identified in Brazil (P.1) are partially escaping protection provided by their vaccines. Specifically, mutations in the viruses’ spike proteins allow them to avoid being bound by antibodies produced after vaccination or natural infection. “The South African variant appears to partially escape antibody responses,” says Dan Barouch, the director of the Center for Virology and Vaccine Research at Beth Israel Deaconess Medical Center in Boston. With novel variants expected to emerge, the question is, which vaccines would be quickest to rejig and manufacture if updates become necessary? ....